Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1964 1
1965 3
1966 2
1967 1
1968 3
1969 2
1970 3
1971 4
1972 4
1973 4
1974 8
1975 9
1976 4
1977 11
1978 8
1979 8
1980 8
1981 9
1982 5
1983 2
1984 7
1985 1
1986 8
1987 18
1988 15
1989 11
1990 10
1991 17
1992 14
1993 9
1994 6
1995 6
1996 11
1997 5
1998 7
1999 4
2000 9
2001 5
2002 6
2003 5
2004 6
2005 7
2006 5
2007 3
2008 9
2009 7
2010 7
2011 10
2012 13
2013 14
2014 18
2015 8
2016 10
2017 16
2018 19
2019 18
2020 15
2021 16
2022 21
2023 18
2024 20
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

524 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Cowan AJ, et al. Among authors: coffey dg. JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003. JAMA. 2022. PMID: 35103762 Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: coffey d. Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6. Blood Cancer J. 2024. PMID: 39030183 Free PMC article.
In reply.
Wright AM, Mody D, Coffey DM. Wright AM, et al. Among authors: coffey dm. Arch Pathol Lab Med. 2014 Mar;138(3):300-1. doi: 10.5858/arpa.2013-0478-LE. Arch Pathol Lab Med. 2014. PMID: 24576020 Free article. No abstract available.
524 results